1-Hydroxy-3-[4-(4-methoxy-phenoxy)-benzenesulfonyl]-azepan-2-one | 1009372-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Hydroxy-3-[4-(4-methoxy-phenoxy)-benzenesulfonyl]-azepan-2-one
• 英文别名: 1-hydroxy-3-[4-(4-methoxyphenoxy)phenyl]sulfonylazepan-2-one
• CAS: 1009372-72-8
• 化学式: C₁₉H₂₁NO₆S
• 分子量: 391.445
• InChiKey: ZCLGRPDLXFVIIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-[4-(4-methoxy-phenoxy)-benzenesulfonyl]-1-trityloxy-azepan-2-one 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以87%的产率得到1-Hydroxy-3-[4-(4-methoxy-phenoxy)-benzenesulfonyl]-azepan-2-one
  参考文献：
  名称：

  Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)

  摘要：

  Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.049

文献信息

• HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS
  申请人：Zhang Yue-Mei

  公开号：US20080103129A1

  公开（公告）日：2008-05-01

  This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  这项发明提供了一种新颖的杂环衍生物基质金属蛋白酶抑制剂的化学式，以及包含同样化合物的药物组合物，用于治疗通过拮抗基质金属蛋白酶而改善的疾病。该发明还提供了使用即时药物组合物的治疗和预防方法。
• Heterocyclic derived metalloprotease inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US07803793B2

  公开（公告）日：2010-09-28

  This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  该发明提供了一种新型杂环衍生物基质金属蛋白酶抑制剂，其化学式为：以及包含其的制药组合物，用于治疗通过拮抗基质金属蛋白酶改善的疾病。此发明还提供了使用上述制药组合物的治疗和预防方法。
• US7803793B2
  申请人：——

  公开号：US7803793B2

  公开（公告）日：2010-09-28
• [EN] HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE MÉTALLOPROTÉASES DÉRIVÉES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2008045668A1

  公开（公告）日：2008-04-17

  [EN] This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula (I) and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
  [FR] L'objet de la présente invention propose de nouveaux inhibiteurs hétérocycliques de métalloprotéases matricielles dérivées de formule (I) et des composés pharmaceutiques comprenant ces inhibiteurs, qui sont utiles pour traiter des troubles améliorés par des métalloprotéases matricielles antagonistes. Cette invention propose également des méthodes thérapeutiques et prophylactiques mettant en oeuvre les présentes compositions pharmaceutiques.
• Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
  作者：Yue-Mei Zhang、Xiaodong Fan、Shyh-Ming Yang、Robert H. Scannevin、Sharon L. Burke、Kenneth J. Rhodes、Paul F. Jackson

  DOI：10.1016/j.bmcl.2007.10.049

  日期：2008.1

  Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.